Synthesis and in vitro characterization of drug conjugates of l-carnitine as potential prodrugs that target human Octn2

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3802-3816

  Diao, Lei ^a   Polli, James E ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Carnitine; Prodrugs; Renal reabsorption; Site specific delivery; Stability; Substrate; Transporters

Indexed keywords

CARNITINE; CARNITINE DERIVATIVE; CARRIER PROTEIN; KETOPROFEN; KETOPROFEN GLYCINE L CARNITINE; KETOPROFEN GLYCOLIC ACID L CARNITINE; KETOPROFEN L CARNITINE; NAPROXEN; NAPROXEN L CARNITINE; ORGANIC CATION CARNITINE TRANSPORTER; PRODRUG; UNCLASSIFIED DRUG; VALPROYL L CARNITINE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN;

EID: 79960110586     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22557     Document Type: Article

References (32)

1. Bieber LL. 1988. Carnitine. Annu Rev Biochem 57:261-283.
2. Rebouche CJ, Paulson DJ. 1986. Carnitine metabolism and function in humans. Annu Rev Nutr 6:41-66.
3. Pettegrew JW, Levine J, McClure RJ. 2000. Acetyl-l-carnitine physical-chemical, metabolic, and therapeutic properties: Relevance for its mode of action in Alzheimer's disease and geriatric depression. Mol Psychiatry 5:616-632.
4. Koepsell H, Lips K, Volk C. 2007. Polyspecific organic cation transporters: Structure, function, physiological roles, and biopharmaceutical implications. Pharm Res 24:1227-1251.
5. Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. 2008. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Drug Metab Pharmacokinet 23:207-215.
6. Tamai I, China K, Sai Y, Kobayashi D, Nezu J, Kawahara E, Tsuji A. 2001. Na(+)-coupled transport of l-carnitine via high-affinity carnitine transporter OCTN2 and its subcellular localization in kidney. Biochim Biophys Acta 1512:273-284.
7. Yokogawa K, Higashi Y, Tamai I, Nomura M, Hashimoto N, Nikaido H, Hayakawa J, Miyamoto K, Tsuji A. 1999. Decreased tissue distribution of l-carnitine in juvenile visceral steatosis mice. J Pharmacol Exp Ther 289:224-230.
8. Nezu J, Tamai I, Oku A, Ohashi R, Yabuuchi H, Hashimoto N, Nikaido H, Sai Y, Koizumi A, Shoji Y, Takada G, Matsuishi T, Yoshino M, Kato H, Ohura T, Tsujimoto G, Hayakawa J, Shimane M, Tsuji A. 1999. Primary systemic carnitine deficiency is caused by mutations in a gene encoding sodium ion-dependent carnitine transporter. Nat Genet 21:91-94.
9. Wang Y, Ye J, Ganapathy V, Longo N. 1999. Mutations in the organic cation/carnitine transporter OCTN2 in primary carnitine deficiency. Proc Natl Acad Sci U S A 96:2356-2360.
10. Tein I. 2003. Carnitine transport: Pathophysiology and metabolism of known molecular defects. J Inherit Metab Dis 26:147-169.
11. Ohashi R, Tamai I, Yabuuchi H, Nezu JI, Oku A, Sai Y, Shimane M, Tsuji A. 2009. Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): Its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291:778-784.
12. Wu X, Huang W, Prasad PD, Seth P, Rajan DP, Leibach FH, Chen J, Conway SJ, Ganapathy V. 1999. Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J Pharmacol Exp Ther 290:1482-1492.
13. Ganapathy ME, Huang W, Rajan DP, Carter AL, Sugawara M, Iseki K, Leibach FH, Ganapathy V. 2000. Beta-lactam antibiotics as substrates for OCTN2, an organic cation/carnitine transporter. J Biol Chem 275:1699-1707.
14. 0, +. Am J Physiol Gastrointest Liver Physiol 293:G1046-G1053.
15. Grigat S, Fork C, Bach M, Golz S, Geerts A, Schömig E, Gründemann D. 2009. The carnitine transporter SLC22A5 is not a general drug transporter, but it efficiently translocates mildronate. Drug Metab Dispos 37:330-337.
16. Napolitano C, Scaglianti M, Scalambra E, Manfredini S, Ferraro L, Beggiato S, Vertuani S. 2009. Carnitine conjugate of nipecotic acid: A new example of dual prodrug. Molecules 14:3268-3274.
17. Pourfarzams M, Bartlett K. 1991. Synthesis, characterisation and high-performance liquid chromatography of C6-C16 dicarboxylyl-mono-coenzyme A and -mono-carnitine esters. J Chromatogr 570:253-276.
18. Wuts PGM, Greene TW. 2006. Greene's protective groups in organic synthesis. 4th edn. New Jersey: Wiley-Interscience.
19. Diao L, Ekins S, Polli JE. 2009. Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res 26:1890-1900.
20. Rais R, Gonzalez PM, Zheng X, Wring SA, Polli JE. 2008. Method to screen substrates of apical sodium-dependent bile acid transporter. AAPS J 10:596-605.
21. Florea BI, Cassara ML, Junginger HE, Borchard G. 2003. Drug transport and metabolism characteristics of the human airway epithelial cell line Calu-3. J Control Release 87:131-138.
22. Forbes B, Ehrhardt C. 2005. Human respiratory epithelial cell culture for drug delivery applications. Eur J Pharm Biopharm 60:193-205.
23. Endter S, Francombe D, Ehrhardt C, Gumbleton M. 2009. RT-PCR analysis of ABC, SLC and SLCO drug transporters in human lung epithelial cell models. J Pharm Pharmacol 61:583-591.
24. Buchwald P. 2001. Structure-metabolism relationships: Steric effects and the enzymatic hydrolysis of carboxylic esters. Mini Rev Med Chem 1:101-111.
25. Marzo A, Arrigoni ME, Mancinelli A, Cardace G, Corbelletta C, Bassani E, Solbiati M. 1991. Protein binding of l-carnitine family components. Eur J Drug Metab Pharmacokinet 3:364-368.
26. Haas M, Moolenaar, F, Meijer DK, de Zeeuw D. 2002. Specific drug delivery to the kidney. Cardiovasc Drugs Ther 16:489-496.
27. Franssen EJ, Moolenaar F, de Zeeuw D, Meijer DK. 1993. Low molecular weight proteins as carriers for renal drug targeting: Naproxen coupled to lysozyme via the spacer l-lactic acid. Pharm Res 10:963-969.
28. Haas M, Moolenaar F, Meijer DK, de Jong PE, de Zeeuw D. 1998. Renal targeting of a non-steroidal anti-inflammatory drug: Effects on renal prostaglandin synthesis in the rat. Clin Sci 95:603-609.
29. Inano A, Sai Y, Nikaido H, Hasimoto N, Asano M, Tsuji A, Tamai I. 2003. Acetyl-l-carnitine permeability across the blood-brain barrier and involvement of carnitine transporter OCTN2. Biopharm Drug Dispos 24:357-365.
30. Kido Y, Tamai I, Ohnari A, Sai Y, Kagami T, Nezu J, Nikaido H, Hashimoto N, Asano M, Tsuji A. 2001. Functional relevance of carnitine transporter OCTN2 to brain distribution of l-carnitine and acetyl-l-carnitine across the blood-brain barrier. J Neurochem 79:959-969.
31. Monti B, Polazzi E, Contestabile A. 2009. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2:95-109.
32. Brass EP. 2002. Pivalate-generating prodrugs and carnitine homeostasis in man. Pharmacol Rev 54:589-598.